Use of C-terminal domain of IGFBP-5 comprising heparin-binding domain as an angiogenesis inhibitor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 7, 2015
Grant Date -
Apr 10, 2014
app pub date -
Oct 9, 2013
filing date -
Oct 9, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a pharmaceutical composition for inhibiting angiogenesis comprising an isolated peptide comprising the heparin-binding domain of insulin-like growth factor-binding protein-5 (IGFBP-5), a method for inhibiting angiogenesis using the peptide, a pharmaceutical composition for the prevention or treatment of cancer comprising the peptide, a method for treating cancer using the peptide, a novel angiogenesis-inhibiting peptide derived from heparin-binding domain of IGFBP-5, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide and a transformant comprising the vector.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully